Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Received Consensus “Hold” Recommendation by Brokerages

0

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) received an average rating of “Hold” from the fifteen research companies that cover the title, reports Marketbeat.com. Seven equity research analysts rated the stock with a hold recommendation and three gave the company a buy recommendation. The 1-year average price target among analysts who have reported on the stock in the past year is $45.83.

The FMS has been the subject of several reports by research analysts. Berenberg Bank lowered its price target on Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a Wednesday, August 10 report. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its price target for the stock from $30.30 to $33.70 in a research note from Monday, June 27. StockNews.com downgraded Fresenius Medical Care AG & Co. KGaA from a “strong buy” rating to a “buy” rating in a Friday, July 15 research note. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research report. Finally, JPMorgan Chase & Co. reduced its price target on Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report from the Monday, August 1.

Hedge funds weigh on Fresenius Medical Care AG & Co. KGaA

pixel

A d Tradewins

The safest option in the trades!

If you’re new to trading, you’ve probably heard the wrong word about options, that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering strategy, you will soon learn that the safest option for new accounts is the options themselves!

Several institutional investors have recently bought and sold shares of the company. Pzena Investment Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 13.8% in the second quarter. Pzena Investment Management LLC now owns 13,176,037 shares of the company worth $328,610,000 after purchasing an additional 1,598,405 shares in the last quarter. First Trust Advisors LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% in the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company worth $62,496,000 after purchasing an additional 252,768 shares in the last quarter. Cambiar Investors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% in the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company worth $45,935,000 after purchasing an additional 210,819 shares in the last quarter. Bank of America Corp DE increased its stake in Fresenius Medical Care AG & Co. KGaA by 27.9% in the first quarter. Bank of America Corp DE now owns 1,083,689 shares of the company worth $36,499,000 after purchasing an additional 236,459 shares in the last quarter. Finally, Millennium Management LLC acquired a new equity stake in Fresenius Medical Care AG & Co. KGaA during the second quarter at a value of $16,738,000. 4.73% of the shares are held by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA share performance

FMS stock opened at $18.39 on Thursday. The stock has a market capitalization of $10.78 billion, a PE ratio of 11.71, a growth price-earnings ratio of 0.92 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt ratio of 0.47. The stock’s 50-day simple moving average is $22.88 and its 200-day simple moving average is $28.87.

About Fresenius Medical Care AG & Co. KGaA

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

See also

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Fresenius Medical Care AG & Co. KGaA didn’t make the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.